Leucadia Therapeutics
- Medical device or technology
- Biotech or pharma, therapeutic R&D
Leucadia Therapeutics is revolutionizing brain health with a minimally invasive implantable device that restores a critical clearance pathway lost to aging—offering a bold new way to reverse early Alzheimer’s and cognitive decline. Our first-in-human clinical trial begins this September for mild cognitive impairment due to Alzheimer’s, with a 20–25% success probability that could yield a 100x return by delivering the first effective treatment for this devastating disease.
Backed by $9.5M in grants and private capital, we’re fully funded for our initial trial. With a scalable go-to-market strategy targeting a $20B+ market by 2050, we’re poised for exponential growth. While not raising now, we’re open to strategic partnerships and early Series A discussions this Fall to accelerate our mission.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}